

National Health (Minimum Stockholding) Determination 2023

PB 65 of 2023

made under subsection 99AEKC(2) of the

National Health Act 1953

**Compilation No. 18**

**Compilation date:** 1 March 2025

**Includes amendments:** F2025L00213

**About this compilation**

**This compilation**

This is a compilation of the *National Health (Minimum Stockholding) Determination 2023* that shows the text of the law as amended and in force on 1 March 2025 (the ***compilation date***).

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of provisions of the compiled law.

**Uncommenced amendments**

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.

**Application, saving and transitional provisions for provisions and amendments**

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

**Editorial changes**

For more information about any editorial changes made in this compilation, see the endnotes.

**Modifications**

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the Register for the compiled law.

**Self‑repealing provisions**

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

Part 1—Preliminary 1

1 Name 1

3 Authority 1

4 Definitions 1

5 Usual PBS demand 1

Part 2—Minimum stockholding requirement 3

6 Applicable quantity of a brand of a pharmaceutical item 3

Schedule 1—Applicable quantity of a brand of a pharmaceutical item 4

Endnotes 48

Endnote 1—About the endnotes 48

Endnote 2—Abbreviation key 49

Endnote 3—Legislation history 50

Endnote 4—Amendment history 52

Part 1—Preliminary

1 Name

 (1) This instrument is the *National Health (Minimum Stockholding) Determination 2023*.

 (2) This instrument may also be cited as PB 65 of 2023.

3 Authority

 This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Definitions

 In this instrument:

***Act*** means the *National Health Act 1953*.

***brand*** has the same meaning as in Part VII of the Act.

***data collection period*** has the same meaning as in the *National Health (Pharmaceutical Benefits) Regulations 2017*.

***pharmaceutical benefit*** has the same meaning as in Part VII of the Act.

***pharmaceutical item*** has the same meaning as in Part VII of the Act.

***pricing quantity*** has the same meaning as in Part VII of the Act.

***usual demand***, when used in relation to a brand of a pharmaceutical item, means the usual demand for the brand of the pharmaceutical item within the meaning of section 99AEKC of the Act.

***usual PBS*** ***demand***, when used in relation to a brand of a pharmaceutical item, means the usual PBS demand for the brand of the pharmaceutical item ascertained in accordance with section 5.

5 Usual PBS demand

 (1) The usual PBS demand for a brand of a pharmaceutical item for a month in a data collection period for that brand is the number of packs of the brand supplied during the data collection period (***the reference period***) before the previous data collection period for the brand divided by the number of months in the reference period.

 (2) For the purposes of subsection (1) the number of packs of the brand supplied during a data collection period is taken to be:

 (a) the number of packs of the brand supplied as pharmaceutical benefits during that period; and

 (b) adjusted as if the size of the pack equals the pricing quantity of the brand.

 (3) For the purposes of this section, a brand of pharmaceutical item to which section 99ADHC and therefore 99AEKA of the Act applies, but to which section 99ADD of the Act does not apply, is treated as if data collection periods applied to the brand, and as if the start day for the first data collection period for the brand was the day on which that brand was first determined under subsection 85(6) of the Act.

Part 2—Minimum stockholding requirement

6 Applicable quantity of a brand of a pharmaceutical item

 For the purposes of subparagraphs 99AEKC(1)(a)(ii) and (1)(b)(ii) of the Act, if a brand of a pharmaceutical item is specified in an item of column 4 of the table in Schedule 1 to this instrument, the quantity ascertained in accordance with column 5 of that item is the applicable quantity of the brand of the pharmaceutical item.

Schedule 1—Applicable quantity of a brand of a pharmaceutical item

Note: See section 6.

| Applicable quantity of a brand of a pharmaceutical item |
| --- |
| Column 1Drug | Column 2Form | Column 3Manner of administration | **Column 4Brand** | Column 5Applicable quantity |
| Abacavir with lamivudine | Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg | Oral | Abacavir/Lamivudine Viatris | after 31 December 2024—4 months stock by reference to usual demand of both Abacavir/Lamivudine Viatris and Abacavir/Lamivudine Mylan added together |
| Acamprosate | Tablet (enteric coated) containing acamprosate calcium 333 mg | Oral | Acamprosate Viatris | after 30 July 2024—4 months stock by reference to usual demand of both Acamprosate Viatris and Acamprosate Mylan added together |
| Acarbose | Tablet 100 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |
| Acarbose | Tablet 50 mg | Oral | Acarbose Viatris | after 30 July 2024—4 months stock by reference to usual demand of both Acarbose Viatris and Acarbose Mylan added together |
| Acarbose | Tablet 50 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |
| Aciclovir | Tablet 200 mg | Oral | Aciclovir APOTEX | 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX‑ACICLOVIR added together |
| Aciclovir | Tablet 200 mg | Oral | ARX‑ACICLOVIR | 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX‑ACICLOVIR added together |
| Aciclovir | Tablet 800 mg | Oral | Aciclovir APOTEX | 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX‑ACICLOVIR added together |
| Aciclovir | Tablet 800 mg | Oral | ARX‑ACICLOVIR | 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX‑ACICLOVIR added together |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral | Fosamax Plus 70 mg/140 mcg | between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | Oral | Fosamax Plus | between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand |
| Allopurinol | Tablet 100 mg | Oral | Allosig | 3 months stock by reference to usual demand |
| Allopurinol | Tablet 100 mg | Oral | APO‑ALLOPURINOL | 4 months stock by reference to usual demand of both Allopurinol APOTEX and APO‑ALLOPURINOL added together |
| Allopurinol | Tablet 100 mg | Oral | Zyloprim | 3 months stock by reference to usual demand |
| Allopurinol | Tablet 300 mg | Oral | APO‑ALLOPURINOL | 6 months stock by reference to usual demand of both Allopurinol APOTEX and APO‑ALLOPURINOL added together |
| Allopurinol | Tablet 300 mg | Oral | Zyloprim | 4 months stock by reference to usual demand |
| Amino acid formula with vitamins and minerals without lysine and low in tryptophan | Sachets containing oral powder 24 g, 30 (GA gel) | Oral | GA gel | 0 months stock by reference to usual PBS demand |
| Amino acid formula with vitamins and minerals without phenylalanine | Oral gel 85 g, 30 (PKU squeezie) | Oral | PKU squeezie | 0 months stock by reference to usual PBS demand |
| Amisulpride | Oral solution 100 mg per mL, 60 mL | Oral | Solian Solution | 4 months stock by reference to usual PBS demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral | ENTRIP | 4 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | APX‑Amitriptyline | 5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | ENTRIP | 4 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | APX‑Amitriptyline | 4.5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | ENTRIP | 4.5 months stock by reference to usual demand |
| Amlodipine | Tablet 5 mg (as besilate) | Oral | APX‑AMLODIPINE | 6 months stock by reference to usual demand of both Amlodipine APOTEX and APX‑AMLODIPINE added together |
| Amoxicillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | 4 months stock by reference to usual PBS demand |
| Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AlphaClav Duo Forte Viatris | 6 months stock by reference to usual demand |
| Amphotericin B | Lozenge 10 mg | Oral | Fungilin | 4 months stock by reference to usual PBS demand |
| Anakinra | Injection 100 mg in 0.67 mL single use pre‑filled syringe | Injection | Kineret | 6 months stock by reference to usual PBS demand |
| Aripiprazole | Tablet 10 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 15 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 15 mg | Oral | Aripic Aripiprazole | between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand |
| Aripiprazole | Tablet 20 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 20 mg | Oral | Aripic Aripiprazole | between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand |
| Aripiprazole | Tablet 30 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 30 mg | Oral | Aripic Aripiprazole | between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand |
| Atenolol | Oral solution 50 mg in 10 ml, 300 ml | Oral | Atenolol‑AFT | (a) between 1 January 2025 and 31 May 2025—4 months stock by reference to usual PBS demand(b) after 31 May 2025—6 months stock by reference to usual PBS demand |
| Atenolol | Tablet 50 mg | Oral | APX‑Atenolol | 4 months stock by reference to usual demand |
| Atenolol | Tablet 50 mg | Oral | Tensig | 4 months stock by reference to usual demand |
| Atomoxetine | Capsule 10 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 100 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 18 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 25 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 40 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 60 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 80 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Azacitidine | Powder for injection 100 mg | Injection | Azacitidine‑Teva | between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand |
| Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL | Oral | Zithromax | 4 months stock by reference to usual PBS demand |
| Azithromycin | Tablet 500 mg (as dihydrate) | Oral | Azithromycin Viatris | after 30 September 2024—4 months stock by reference to usual demand of both Azithromycin Viatris and Azithromycin Mylan added together |
| Baclofen | Tablet 10 mg | Oral | APO‑Baclofen | 3 months stock by reference to usual demand |
| Benzathine benzylpenicillin | Injection containing 1,200,000 units benzathine benzylpenicillin tetrahydrate in 2.3 mL single use pre‑filled syringe | Injection | Bicillin L‑A | 6 months stock by reference to usual PBS demand |
| Benzathine benzylpenicillin | Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre‑filled syringe | Injection | Bicillin L‑A | 6 months stock by reference to usual PBS demand |
| Bisacodyl | Tablet 5 mg | Oral | Lax‑Tab | between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand |
| Bivalirudin | Powder for I.V. injection 250 mg (as trifluoroacetate) | Injection | Bivalirudin APOTEX | 4 months stock by reference to usual demand of both Bivalirudin APOTEX and BIVALIRUDIN ARX added together |
| Bivalirudin | Powder for I.V. injection 250 mg (as trifluoroacetate) | Injection | BIVALIRUDIN ARX | 4 months stock by reference to usual demand of both Bivalirudin APOTEX and BIVALIRUDIN ARX added together |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | Bosentan APO | 3 months stock by reference to usual demand |
| Budesonide | Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 | Inhalation | Pulmicort Respules | 6 months stock by reference to usual PBS demand |
| Budesonide | Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses | Inhalation by Mouth | Pulmicort Turbuhaler | 6 months stock by reference to usual PBS demand |
| Calcium | Tablet, chewable, 500 mg (as carbonate) | Oral | Cal‑500 | 6 months stock by reference to usual PBS demand |
| Captopril | Oral solution 5 mg per mL, 95 mL | Oral | Capoten | 4 months stock by reference to usual PBS demand |
| Cefazolin | Powder for injection 1 g (as sodium) | Injection | Cefazolin‑AFT | 300,000 packs of a pack quantity of 5 |
| Cefazolin | Powder for injection 2 g (as sodium) | Injection | Cephazolin Viatris | after 30 July 2024—6 months stock by reference to usual demand of both Cephazolin Viatris and Cephazolin Alphapharm added together |
| Ceftriaxone | Powder for injection 1 g (as sodium) | Injection | Ceftriaxone Viatris | after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together |
| Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone Viatris | after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together |
| Chloramphenicol | Eye drops 5 mg per mL, 10 mL | Application to the Eye | Chlorsig | 4 months stock by reference to usual PBS demand |
| Chlorpromazine | Injection containing chlorpromazine hydrochloride 50 mg in 2 mL | Injection | Largactil | 6 months stock by reference to usual PBS demand |
| Chlorpromazine | Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL | Oral | Largactil | 6 months stock by reference to usual PBS demand |
| Chlorpromazine | Tablet containing chlorpromazine hydrochloride 100 mg | Oral | Largactil | 6 months stock by reference to usual PBS demand |
| Chlorpromazine | Tablet containing chlorpromazine hydrochloride 25 mg | Oral | Largactil | 6 months stock by reference to usual PBS demand |
| Chlortalidone | Tablet 25 mg | Oral | Hygroton 25 | 4 months stock by reference to usual PBS demand |
| Ciclosporin | Capsule 10 mg | Oral | Neoral 10 | 4 months stock by reference to usual PBS demand |
| Ciclosporin | Capsule 100 mg | Oral | APO‑Ciclosporin | 2.5 months stock by reference to usual demand |
| Ciclosporin | Capsule 100 mg | Oral | Cyclosporin Sandoz | between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand |
| Ciclosporin | Capsule 25 mg | Oral | APO‑Ciclosporin | 3 months stock by reference to usual demand |
| Ciclosporin | Capsule 25 mg | Oral | Cyclosporin Sandoz | between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand |
| Ciclosporin | Capsule 50 mg | Oral | APO‑Ciclosporin | 3 months stock by reference to usual demand |
| Ciclosporin | Capsule 50 mg | Oral | Cyclosporin Sandoz | between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand |
| Ciclosporin | Oral liquid 100 mg per mL, 50 mL | Oral | Neoral | 4 months stock by reference to usual PBS demand |
| Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL | Oral | Klacid | 4 months stock by reference to usual PBS demand |
| Clonazepam | Oral liquid 2.5 mg per mL, 10 mL | Oral | Rivotril | 6 months stock by reference to usual PBS demand |
| Clopidogrel with aspirin | Tablet 75 mg (as hydrogen sulfate)‑100 mg | Oral | Clopidogrel Winthrop plus aspirin | between 1 December 2024 and 31 March 2025—0 months stock by reference to usual demand |
| Codeine | Tablet containing codeine phosphate hemihydrate 30 mg | Oral | Aspen Pharmacare Australia Pty Ltd | 4 months stock by reference to usual PBS demand |
| Dantrolene | Capsule containing dantrolene sodium hemiheptahydrate 25 mg | Oral | Dantrium | 6 months stock by reference to usual PBS demand |
| Diazepam | Oral liquid 10 mg per 10 mL, 100 mL | Oral | Diazepam Elixir | 4 months stock by reference to usual PBS demand |
| Diphtheria and tetanus vaccine, adsorbed, diluted for adult use | Injection 0.5 mL in pre‑filled syringe | Injection | ADT Booster | 6 months stock by reference to usual PBS demand |
| Dolutegravir with abacavir and lamivudine | Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg | Oral | Triumeq | 6 months stock by reference to usual PBS demand |
| Dosulepin | Capsule containing dosulepin hydrochloride 25 mg | Oral | Dosulepin Viatris | after 31 May 2024—6 months stock by reference to usual demand of both Dosulepin Viatris and Dosulepin Mylan added together |
| Doxorubicin ‑ pegylated liposomal | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL | Injection | Liposomal Doxorubicin SUN | 3 months stock by reference to usual demand |
| Doxorubicin ‑ pegylated liposomal | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL | Injection | Liposomal Doxorubicin SUN | 3 months stock by reference to usual demand |
| Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX‑Doxycycline | 5.5 months stock by reference to usual demand |
| Doxycycline | Tablet 50 mg (as hyclate) | Oral | Doxsig | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | APO‑Enalapril | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | Malean | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 20 mg | Oral | APO‑Enalapril | 3 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 20 mg | Oral | Malean | 3 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Acetec | 2 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | APO‑Enalapril | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Malean | 4 months stock by reference to usual demand |
| Entecavir | Tablet 0.5 mg (as monohydrate) | Oral | Entecavir Viatris | after 30 September 2024—4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together |
| Entecavir | Tablet 1 mg (as monohydrate) | Oral | Entecavir Viatris | after 28 February 2025— 4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together |
| Escitalopram | Oral solution 20 mg (as oxalate) per mL, 15 mL | Oral | Lexapro | 4 months stock by reference to usual PBS demand |
| Escitalopram | Tablet 10 mg (as oxalate) | Oral | APX‑Escitalopram | 4 months stock by reference to usual demand |
| Escitalopram | Tablet 20 mg (as oxalate) | Oral | APX‑Escitalopram | 4 months stock by reference to usual demand |
| Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | after 31 December 2024—4 months stock by reference to usual demand of both Esomeprazole Viatris and Esomeprazole Mylan added together |
| Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | after 31 December 2024—4 months stock by reference to usual demand of both Esomeprazole Viatris and Esomeprazole Mylan added together |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | APO‑Ezetimibe/Simvastatin 10/10 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | APO‑Ezetimibe/Simvastatin 10/20 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | APO‑Ezetimibe/Simvastatin 10/40 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | APO‑Ezetimibe/Simvastatin 10/80 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Felodipine | Tablet 2.5 mg (extended release) | Oral | Felodur ER 2.5 mg | 2.5 months stock by reference to usual demand |
| Felodipine | Tablet 2.5 mg (extended release) | Oral | Plendil ER | 2.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 10.20 mg | Transdermal | Denpax | 2.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 12.6 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 16.8 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 2.1 mg | Transdermal | APO‑Fentanyl | 3.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 4.2 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 5.10 mg | Transdermal | Denpax | 2.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 8.4 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
| Fluconazole | Capsule 200 mg | Oral | APO‑Fluconazole | 4 months stock by reference to usual demand of both Fluconazole APOTEX and APO‑Fluconazole added together |
| Fluconazole | Powder for oral suspension 50 mg in 5 mL, 35 mL | Oral | Diflucan | 4 months stock by reference to usual PBS demand |
| Folic acid | Tablet 5 mg | Oral | Megafol 5 | 4 months stock by reference to usual PBS demand |
| Folic acid | Tablet 500 micrograms | Oral | Foltabs 500 | 4 months stock by reference to usual PBS demand |
| Folic acid | Tablet 500 micrograms | Oral | Megafol 0.5 | 4 months stock by reference to usual PBS demand |
| Fosinopril | Tablet containing fosinopril sodium 10 mg | Oral | APO‑Fosinopril | 3 months stock by reference to usual demand |
| Fosinopril | Tablet containing fosinopril sodium 20 mg | Oral | APO‑Fosinopril | 3 months stock by reference to usual demand |
| Framycetin | Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL | Application to the Eye/Ear | Soframycin | 4 months stock by reference to usual PBS demand |
| Furosemide | Oral solution 10 mg per ml, 30 ml | Oral | Lasix | (a) between 1 November 2024 and 31 March 2025—4 months stock by reference to usual PBS demand(b) after 31 March 2025—6 months stock by reference to usual PBS demand |
| Fusidic acid | Tablet containing sodium fusidate 250 mg | Oral | Fucidin | 6 months stock by reference to usual PBS demand |
| Gabapentin | Capsule 400 mg | Oral | GAPENTIN | 3 months stock by reference to usual demand |
| Gabapentin | Tablet 600 mg | Oral | APX‑GABAPENTIN | 4 months stock by reference to usual demand of both Gabapentin APOTEX and APX‑GABAPENTIN added together |
| Galantamine | Capsule (prolonged release) 16 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 24 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Galantyl | 1.5 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Glimepiride | Tablet 1 mg | Oral | ARX‑GLIMEPIRIDE | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX‑GLIMEPRIDE added together |
| Glimepiride | Tablet 1 mg | Oral | Glimepiride APOTEX | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX‑GLIMEPRIDE added together |
| Glimepiride | Tablet 2 mg | Oral | ARX‑GLIMEPIRIDE | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX‑GLIMEPRIDE added together |
| Glimepiride | Tablet 2 mg | Oral | Glimepiride APOTEX | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX‑GLIMEPRIDE added together |
| Glimepiride | Tablet 3 mg | Oral | ARX‑GLIMEPIRIDE | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX‑GLIMEPRIDE added together |
| Glimepiride | Tablet 3 mg | Oral | Glimepiride APOTEX | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX‑GLIMEPRIDE added together |
| Glimepiride | Tablet 4 mg | Oral | ARX‑GLIMEPIRIDE | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX‑GLIMEPRIDE added together |
| Glimepiride | Tablet 4 mg | Oral | Glimepiride APOTEX | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX‑GLIMEPRIDE added together |
| Glucose and ketone indicator‑urine | Test strips, 50 (Keto‑Diastix) | For External Use | Keto‑Diastix | 4 months stock by reference to usual PBS demand |
| Glyceryl trinitrate | Transdermal patch 36 mg | Transdermal | Minitran 10 | between 1 February 2025 and 30 September 2025—0 months stock by reference to usual demand |
| Glyceryl trinitrate | Transdermal patch 54 mg | Transdermal | Minitran 15 | between 1 February 2025 and 31 December 2025—0 months stock by reference to usual demand |
| Haloperidol | Tablet 1.5 mg | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 5 mg | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 500 micrograms | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Heparin | Injection 5,000 units (as sodium) in 0.2 ml | Injection | DBL Heparin Sodium | 6 months stock by reference to usual PBS demand |
| Hypromellose with carbomer 980 | Ocular lubricating gel 3 mg‑2 mg per g, 10 g | Application to the Eye | Genteal gel | between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand |
| Hypromellose with carbomer 980 | Ocular lubricating gel 3 mg‑2 mg per g, 10 g | Application to the Eye | HPMC PAA | between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | ARX‑IMATINIB | 3 months stock by reference to usual demand of both Imatinib‑APOTEX and ARX‑IMATINIB added together |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | Imatinib‑APOTEX | 3 months stock by reference to usual demand of both Imatinib‑APOTEX and ARX‑IMATINIB added together |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | ARX‑IMATINIB | 3 months stock by reference to usual demand of both Imatinib‑APOTEX and ARX‑IMATINIB added together |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | Imatinib‑APOTEX | 3 months stock by reference to usual demand of both Imatinib‑APOTEX and ARX‑IMATINIB added together |
| Indapamide | Tablet containing indapamide hemihydrate 2.5 mg | Oral | Insig | 3 months stock by reference to usual demand |
| Insect allergen extract‑honey bee venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Honey Bee Venom | 6 months stock by reference to usual PBS demand |
| Insect allergen extract‑paper wasp venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Paper Wasp Venom | 6 months stock by reference to usual PBS demand |
| Insect allergen extract‑yellow jacket venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Yellow Jacket Venom | 6 months stock by reference to usual PBS demand |
| Irbesartan with hydrochlorothiazide | Tablet 150 mg‑12.5 mg | Oral | AVSARTAN HCT 150/12.5 | 4 months stock by reference to usual demand |
| Iron polymaltose complex | Injection 100 mg (iron) in 2 mL | Injection | Ferrosig | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Isoleucine with carbohydrate | Sachets of oral powder 4 g containing 1 g isoleucine, 30 (Isoleucine 1000) | Oral | Isoleucine 1000 | 0 months stock by reference to usual PBS demand |
| Isoleucine with carbohydrate | Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50) | Oral | Isoleucine 50 | 0 months stock by reference to usual PBS demand |
| Labetalol | Tablet containing labetalol hydrochloride 100 mg | Oral | Presolol 100 | between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand |
| Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | APO‑Lansoprazole ODT | 4.5 months stock by reference to usual demand |
| Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | APO‑Lansoprazole ODT | 3 months stock by reference to usual demand |
| Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the Eye | APO‑Latanoprost | 2 months stock by reference to usual demand |
| Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the Eye | APO‑Latanoprost/Timolol 0.05/5 | 2.5 months stock by reference to usual demand |
| Leflunomide | Tablet 10 mg | Oral | APO‑LEFLUNOMIDE | 4 months stock by reference to usual demand of both Leflunomide APOTEX and APO‑LEFLUNOMIDE added together |
| Leflunomide | Tablet 20 mg | Oral | APO‑LEFLUNOMIDE | 4 months stock by reference to usual demand of both Leflunomide APOTEX and APO‑LEFLUNOMIDE added together |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral | ARX‑LERCANIDIPINE | 6 months stock by reference to usual demand of both Lercanidipine APOTEX and ARX‑LERCANIDIPINE added together |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 20 mg | Oral | ARX‑LERCANIDIPINE | 6 months stock by reference to usual demand of both Lercanidipine APOTEX and ARX‑LERCANIDIPINE added together |
| Letrozole | Tablet 2.5 mg | Oral | ARX‑LETROZOLE | 4 months stock by reference to usual demand of both Letrozole APOTEX and ARX‑LETROZOLE added together |
| Letrozole | Tablet 2.5 mg | Oral | Letrozole APOTEX | 4 months stock by reference to usual demand of both Letrozole APOTEX and ARX‑LETROZOLE added together |
| Levetiracetam | Tablet 1 g | Oral | Levetiracetam Viatris | after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together |
| Levetiracetam | Tablet 250 mg | Oral | Levetiracetam Viatris | after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together |
| Lithium | Tablet containing lithium carbonate 250 mg | Oral | Lithicarb | 6 months stock by reference to usual PBS demand |
| Lithium | Tablet containing lithium carbonate 450 mg (slow release) | Oral | Quilonum SR | 6 months stock by reference to usual PBS demand |
| Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | Chemists' Own Macrogol with Electrolytes | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |
| Meloxicam | Tablet 7.5 mg | Oral | MELOBIC | 4 months stock by reference to usual demand |
| Methoxyflurane | Liquid for inhalation 999 mg per g, 3 ml (with inhaler) | Inhalation by mouth | Penthrox (Combination Pack) | 6 months stock by reference to usual PBS demand |
| Metoprolol | Tablet containing metoprolol tartrate 100 mg | Oral | Metrol 100 | 4 months stock by reference to usual demand |
| Metronidazole | Suppositories 500 mg, 10 | Rectal | Flagyl | 6 months stock by reference to usual PBS demand |
| Mifepristone and misoprostol | Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms | Oral | MS‑2 Step | 6 months stock by reference to usual PBS demand |
| Milk protein and fat formula with vitamins and minerals ‑‑ carbohydrate free | Oral powder 225 g (Carbohydrate Free Mixture) | Oral | Carbohydrate Free Mixture | 6 months stock by reference to usual PBS demand |
| Modafinil | Tablet 100 mg | Oral | Modafin | 3 months stock by reference to usual demand |
| Modafinil | Tablet 100 mg | Oral | Modafinil Viatris | after 28 February 2025— 4 months stock by reference to usual demand of both Modafinil Viatris and Modafinil Mylan added together |
| Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | APX‑Montelukast | 4 months stock by reference to usual demand of both Montelukast APOTEX and APX‑Montelukast added together |
| Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | APX‑Montelukast | 4 months stock by reference to usual demand of both Montelukast APOTEX and APX‑Montelukast added together |
| Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | ARX‑MYCOPHENOLATE | 4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX‑MYCOPHENOLATE added together |
| Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | Mycophenolate APOTEX | 4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX‑MYCOPHENOLATE added together |
| Nevirapine | Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL | Oral | Viramune | 4 months stock by reference to usual PBS demand |
| Nevirapine | Tablet 200 mg | Oral | Nevirapine Viatris | after 30 November 2024— 4 months stock by reference to usual demand of both Nevirapine Viatris and Nevirapine Alphapharm added together |
| Nevirapine | Tablet 400 mg (extended release) | Oral | Viramune XR | between 1 October 2024 and 30 September 2025—0 months stock by reference to usual demand |
| Nicorandil | Tablets 10 mg, 60 | Oral | APO‑Nicorandil | 2 months stock by reference to usual demand |
| Nicorandil | Tablets 10 mg, 60 | Oral | Ikotab | 2 months stock by reference to usual demand |
| Nicorandil | Tablets 20 mg, 60 | Oral | APO‑Nicorandil | 2 months stock by reference to usual demand |
| Nicorandil | Tablets 20 mg, 60 | Oral | Ikotab | 2 months stock by reference to usual demand |
| Norfloxacin | Tablet 400 mg | Oral | APO‑Norfloxacin | 2.5 months stock by reference to usual demand |
| Olanzapine | Tablet 10 mg | Oral | APO‑OLANZAPINE | 4 months stock by reference to usual demand of both Olanzapine APOTEX and APO‑OLANZAPINE added together |
| Olanzapine | Tablet 10 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 10 mg (orally disintegrating), Oral, added together |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | PRYZEX ODT | 3.5 months stock by reference to usual demand |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together. |
| Olanzapine | Tablet 2.5 mg | Oral | APO‑OLANZAPINE | 6 months stock by reference to usual demand of both Olanzapine APOTEX and APO‑OLANZAPINE added together |
| Olanzapine | Tablet 20 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together |
| Olanzapine | Tablet 5 mg | Oral | APO‑OLANZAPINE | 4 months stock by reference to usual demand of both Olanzapine APOTEX and APO‑OLANZAPINE added together |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | APO‑Olanzapine ODT | 3 months stock by reference to usual demand |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together |
| Olanzapine | Tablet 7.5 mg | Oral | APO‑OLANZAPINE | 4 months stock by reference to usual demand of both Olanzapine APOTEX and APO‑OLANZAPINE added together |
| Olmesartan | Tablet containing olmesartan medoxomil 20 mg | Oral | OLMERTAN | 3 months stock by reference to usual demand |
| Olmesartan | Tablet containing olmesartan medoxomil 40 mg | Oral | OLMERTAN | 3.5 months stock by reference to usual demand |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | Oral | APO‑OLMESARTAN/AMLODIPINE 20/5 | 4 months stock by reference to usual demand of both Olmesartan/Amlodipine 20/5 APOTEX and APO‑OLMESARTAN/AMLODIPINE 20/5 mg added together |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | Oral | APO‑OLMESARTAN/AMLODIPINE 40/10 | 4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/10 APOTEX and APO‑OLMESARTAN/AMLODIPINE 40/10 added together |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | Oral | APO‑OLMESARTAN/AMLODIPINE 40/5 | 4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/5 APOTEX and APO‑OLMESARTAN/AMLODIPINE 40/5 mg added together |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | OLMERTAN COMBI 20/12.5 | 3 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | Oral | OLMERTAN COMBI 40/12.5 | 3 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | Oral | OLMERTAN COMBI 40/25 | 3 months stock by reference to usual demand |
| Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL | Oral | Zofran syrup 50 mL | 4 months stock by reference to usual PBS demand |
| Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | Ondansetron ODT Viatris | after 31 May 2025—4 months stock by reference to usual demand of both Ondansetron ODT Viatris and Ondansetron Mylan ODT added together |
| Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | Ondansetron Tablets Viatris | after 31 May 2025—6 months stock by reference to usual demand of both Ondansetron Tablets Viatris and Ondansetron Mylan Tablets added together |
| Ondansetron | Tablet 8 mg (as hydrochloride dihydrate) | Oral | Ondansetron Tablets Viatris | after 31 May 2025—4 months stock by reference to usual demand of both Ondansetron Tablets Viatris and Ondansetron Mylan Tablets added together |
| Oxazepam | Tablet 30 mg | Oral | APO‑Oxazepam | 5.5 months stock by reference to usual demand |
| Oxazepam | Tablet 30 mg | Oral | Murelax | 5 months stock by reference to usual demand |
| Oxycodone | Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL | Oral | OxyNorm Liquid 1mg/mL | 4 months stock by reference to usual PBS demand |
| Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Oxycodone Viatris | after 28 February 2024—6 months stock by reference to usual demand of both Oxycodone Viatris and Oxycodone Mylan added together |
| Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral | Somac | 4 months stock by reference to usual PBS demand |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APX‑PANTOPRAZOLE | 6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX‑PANTOPRAZOLE added together |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APO‑Pantoprazole | 5.5 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | APX‑PANTOPRAZOLE | 6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX‑PANTOPRAZOLE added together |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | 5.5 months stock by reference to usual demand |
| Periciazine | Tablet 10 mg | Oral | Neulactil | 6 months stock by reference to usual PBS demand |
| Periciazine | Tablet 2.5 mg | Oral | Neulactil | 6 months stock by reference to usual PBS demand |
| Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | Indosyl Mono 2 | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | Indosyl Mono 4 | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 8 mg | Oral | Indosyl Mono 8 | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Indosyl Combi 4/1.25 | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Perindo Combi 4/1.25 | 2.5 months stock by reference to usual demand |
| Permethrin | Cream 50 mg per g, 30 g | Application | Lyclear | 6 months stock by reference to usual PBS demand |
| Pimecrolimus | Cream 10 mg per g, 15 g | Application | Elidel | 6 months stock by reference to usual PBS demand |
| Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | APOTEX‑Pioglitazone | 4 months stock by reference to usual demand of both APOTEX‑Pioglitazone and ARX‑PIOGLITAZONE added together |
| Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | ARX‑PIOGLITAZONE | 4 months stock by reference to usual demand of both APOTEX‑Pioglitazone and ARX‑PIOGLITAZONE added together |
| Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | APOTEX‑Pioglitazone | 4 months stock by reference to usual demand of both APOTEX‑Pioglitazone and ARX‑PIOGLITAZONE added together |
| Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | ARX‑PIOGLITAZONE | 4 months stock by reference to usual demand of both APOTEX‑Pioglitazone and ARX‑PIOGLITAZONE added together |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | APOTEX‑Pioglitazone | 4 months stock by reference to usual demand of both APOTEX‑Pioglitazone and ARX‑PIOGLITAZONE added together |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | ARX‑PIOGLITAZONE | 4 months stock by reference to usual demand of both APOTEX‑Pioglitazone and ARX‑PIOGLITAZONE added together |
| Piroxicam | Dispersible tablet 20 mg | Oral | Feldene‑D | between 1 February 2025 and 31 March 2025—0 months stock by reference to usual demand |
| Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg‑3 mg per mL, 15 mL | Application to the Eye | Optix | between 1 February 2025 and 30 April 2025—0 months stock by reference to usual demand |
| Probenecid | Tablet 500 mg | Oral | Pro‑Cid | 6 months stock by reference to usual PBS demand |
| Prochlorperazine | Injection containing prochlorperazine mesilate 12.5 mg in 1 mL | Injection | Stemetil | 6 months stock by reference to usual PBS demand |
| Promethazine | Injection containing promethazine hydrochloride 50 mg in 2 mL | Injection | DBL Promethazine Hydrochloride | 6 months stock by reference to usual PBS demand |
| Protein hydrolysate formula with medium chain triglycerides | Oral powder 450 g (Aptamil Gold+ Pepti‑Junior) | Oral | Aptamil Gold+ Pepti‑Junior | 6 months stock by reference to usual PBS demand |
| Quetiapine | Tablet 100 mg (as fumarate) | Oral | APX‑QUETIAPINE | 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX‑QUETIAPINE added together |
| Quetiapine | Tablet 200 mg (as fumarate) | Oral | APX‑QUETIAPINE | 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX‑QUETIAPINE added together |
| Quetiapine | Tablet 25 mg (as fumarate) | Oral | APX‑QUETIAPINE | 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX‑QUETIAPINE added together |
| Quetiapine | Tablet 300 mg (as fumarate) | Oral | APX‑QUETIAPINE | 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX‑QUETIAPINE added together |
| Quinapril | Tablet 10 mg (as hydrochloride) | Oral | APO‑Quinapril | 3 months stock by reference to usual demand |
| Quinapril | Tablet 20 mg (as hydrochloride) | Oral | APO‑Quinapril | 3 months stock by reference to usual demand |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | APO‑Rabeprazole | 4 months stock by reference to usual demand |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Parbezol | 4 months stock by reference to usual demand |
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | Oral | RALOVISTA | 3 months stock by reference to usual demand |
| Ramipril | Capsule 10 mg | Oral | APX‑Ramipril | 5.5 months stock by reference to usual demand |
| Ramipril | Capsule 10 mg | Oral | Prilace | 5.5 months stock by reference to usual demand |
| Ramipril | Tablet 1.25 mg | Oral | Prilace | 2.5 months stock by reference to usual demand |
| Ramipril | Tablet 1.25 mg | Oral | Ramipril Viatris | (a) between 1 January 2025 and 28 February 2025—3 months stock by reference to usual demand of Tryzan Tabs 1.25(b) after 28 February 2025—3 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 1.25 added together |
| Ramipril | Tablet 10 mg | Oral | Ramipril Viatris | after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 10 added together |
| Ramipril | Tablet 2.5 mg | Oral | Ramipril Viatris | after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 2.5 added together |
| Ramipril | Tablet 5 mg | Oral | Ramipril Viatris | after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 5 added together |
| Ramipril with felodipine | Tablet 2.5 mg‑2.5 mg (modified release) | Oral | Triasyn 2.5/2.5 | between 1 February 2025 and 30 September 2025—0 months stock by reference to usual PBS demand |
| Risedronic acid | Tablet containing risedronate sodium 150 mg | Oral | APO‑Risedronate | 3 months stock by reference to usual demand |
| Risperidone | Tablet 3 mg | Oral | APO‑Risperidone | 3.5 months stock by reference to usual demand |
| Risperidone | Tablet 3 mg | Oral | Rispa | 3 months stock by reference to usual demand |
| Rizatriptan | Tablet (orally disintegrating) 10 mg (as benzoate) | Oral | APO‑RIZATRIPTAN ODT | 4 months stock by reference to usual demand of both Rizatriptan ODT APOTEX and APO‑RIZATRIPTAN ODT added together |
| Rosuvastatin | Tablet 10 mg (as calcium) | Oral | APO‑Rosuvastatin | 6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO‑Rosuvastatin added together |
| Rosuvastatin | Tablet 20 mg (as calcium) | Oral | APO‑ROSUVASTATIN | 4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO‑ROSUVASTATIN added together |
| Rosuvastatin | Tablet 40 mg (as calcium) | Oral | APO‑ROSUVASTATIN | 4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO‑ROSUVASTATIN added together |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | APO‑ROSUVASTATIN | 6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO‑ROSUVASTATIN added together |
| Roxithromycin | Tablet 150 mg | Oral | APX‑Roxithromycin | 4 months stock by reference to usual demand |
| Roxithromycin | Tablet 300 mg | Oral | APX‑Roxithromycin | 5 months stock by reference to usual demand |
| Sevelamer | Tablet containing sevelamer carbonate 800 mg | Oral | ARX‑SEVELAMER | 4 months stock by reference to usual demand of both Sevelamer Apotex and ARX‑SEVELAMER added together |
| Sevelamer | Tablet containing sevelamer carbonate 800 mg | Oral | Sevelamer Apotex | 4 months stock by reference to usual demand of both Sevelamer Apotex and ARX‑SEVELAMER added together |
| Sodium acid phosphate | Tablet, compound effervescent, equivalent to 500 mg phosphorus | Oral | PHOSPHATE PHEBRA | 6 months stock by reference to usual PBS demand |
| Sotalol | Tablet containing sotalol hydrochloride 160 mg | Oral | Cardol | 1.5 months stock by reference to usual demand |
| Sumatriptan | Tablet 50 mg (as succinate) | Oral | APO‑Sumatriptan | 4 months stock by reference to usual demand |
| Tacrolimus | Capsule 1 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
| Tacrolimus | Capsule 5 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
| Temazepam | Tablet 10 mg | Oral | APO‑Temazepam | 2.5 months stock by reference to usual demand |
| Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Tenofovir APOTEX | 4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together |
| Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Tenofovir ARX | 4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together |
| Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Viread | between 1 January 2025 and 31 March 2025—2 months stock by reference to usual demand |
| Tenofovir | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | Tenofovir Disoproxil Viatris | after 31 January 2025— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Viatris and Tenofovir Disoproxil Mylan added together |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | Tenofovir/Emtricitabine 300/200 APOTEX | 3 months stock by reference to usual demand of both Tenofovir/Emtricitabine 300/200 APOTEX and TENOFOVIR/EMTRICITABINE 300/200 ARX added together |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | TENOFOVIR/EMTRICITABINE 300/200 ARX | 3 months stock by reference to usual demand of both Tenofovir/Emtricitabine 300/200 APOTEX and TENOFOVIR/EMTRICITABINE 300/200 ARX added together |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg | Oral | Tenofovir Disoproxil Emtricitabine Viatris 300/200 | after 30 April 2024—4 months stock by reference to usual demand of both Tenofovir Disoproxil Emtricitabine Viatris 300/200 and Tenofovir Disoproxil Emtricitabine Mylan 300/200 added together |
| Thiamine | Tablet containing thiamine hydrochloride 100 mg | Oral | Betavit | 4 months stock by reference to usual PBS demand |
| Tobramycin | Injection 80 mg (as sulfate) in 2 mL (without preservative) | Injection | Pfizer Australia Pty Ltd | 2 months stock by reference to usual demand |
| Tobramycin | Injection 80 mg in 2 mL | Injection | Tobramycin Viatris | 4 months stock by reference to usual demand of both Tobramycin Viatris and Tobramycin Mylan added together |
| Topiramate | Tablet 100 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 200 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 25 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 50 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |
| Tramadol | Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL | Oral | Tramal | 4 months stock by reference to usual PBS demand |
| Trandolapril | Capsule 1 mg | Oral | Dolapril 1 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 2 mg | Oral | Dolapril 2 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 4 mg | Oral | Dolapril 4 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 500 micrograms | Oral | Dolapril 0.5 | 2.5 months stock by reference to usual demand |
| Trastuzumab | Powder for I.V. infusion 150 mg | Injection | Kanjinti | between 1 February 2025 and 31 March 2025—0 months stock by reference to usual demand |
| Triglycerides—medium chain, formula | Oral powder 400 g (Lipistart) | Oral | Lipistart | 0 months stock by reference to usual PBS demand |
| Trimethoprim | Tablet 300 mg | Oral | Trimethoprim Viatris | after 30 April 2024—6 months stock by reference to usual demand of both Trimethoprim Viatris and Trimethoprim Mylan added together |
| Valganciclovir | Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL | Oral | Valcyte | 4 months stock by reference to usual PBS demand |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000) | Oral | Valine 1000 | 0 months stock by reference to usual PBS demand |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50) | Oral | Valine 50 | 0 months stock by reference to usual PBS demand |
| Valproic acid | Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | Epilim Liquid | (a) between 1 February 2025 and 31 March 2025—89,358 packs of a pack quantity of 1 (b) between 1 April 2025 and 30 September 2025—91,362 packs of a pack quantity of 1 (c) after 30 September 2025—6 months stock by reference to usual PBS demand |
| Valproic acid | Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | Epilim Syrup | 6 months stock by reference to usual PBS demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | APO‑Sodium Valproate | between 1 April 2025 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Epilim EC | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Sodium Valproate Sandoz | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Valprease 200 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Valpro EC 200 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Valproate Winthrop EC 200 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | APO‑Sodium Valproate | between 1 April 2025 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Epilim EC | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Sodium Valproate Sandoz | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Valprease 500 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Valpro EC 500 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Valproate Winthrop EC 500 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
| Valproic acid | Tablet, crushable, containing sodium valproate 100 mg | Oral | Epilim | 4 months stock by reference to usual PBS demand |
| Vancomycin | Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together |
| Vancomycin | Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together |
| Voriconazole | Powder for oral suspension 40 mg per mL, 70 mL | Oral | Vfend | 4 months stock by reference to usual PBS demand |

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

**Abbreviation key—Endnote 2**

The abbreviation key sets out abbreviations that may be used in the endnotes.

**Legislation history and amendment history—Endnotes 3 and 4**

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

**Editorial changes**

The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

**Misdescribed amendments**

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the *Legislation Act 2003*.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

Endnote 2—Abbreviation key

|  |  |
| --- | --- |
| ad = added or inserted | o = order(s) |
| am = amended | Ord = Ordinance |
| amdt = amendment | orig = original |
| c = clause(s) | par = paragraph(s)/subparagraph(s) |
| C[x] = Compilation No. x | /sub‑subparagraph(s) |
| Ch = Chapter(s) | pres = present |
| def = definition(s) | prev = previous |
| Dict = Dictionary | (prev…) = previously |
| disallowed = disallowed by Parliament | Pt = Part(s) |
| Div = Division(s) | r = regulation(s)/rule(s) |
| ed = editorial change | reloc = relocated |
| exp = expires/expired or ceases/ceased to have | renum = renumbered |
| effect | rep = repealed |
| F = Federal Register of Legislation | rs = repealed and substituted |
| gaz = gazette | s = section(s)/subsection(s) |
| LA = *Legislation Act 2003* | Sch = Schedule(s) |
| LIA = *Legislative Instruments Act 2003* | Sdiv = Subdivision(s) |
| (md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
| effect | SR = Statutory Rules |
| (md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
| cannot be given effect | SubPt = Subpart(s) |
| mod = modified/modification | underlining = whole or part not |
| No. = Number(s) | commenced or to be commenced |

Endnote 3—Legislation history

| Name | Registration | Commencement | Application, saving and transitional provisions |
| --- | --- | --- | --- |
| National Health (Minimum Stockholding) Determination 2023 (PB 65 of 2023) | 30 June 2023 (F2023L00919) | 1 July 2023 (s 2(1) item 1) |  |
| National Health (Minimum Stockholding) Amendment Determination (No. 1) 2023 (PB 103 of 2023) | 29 Sept 2023 (F2023L01338) | 1 Oct 2023 (s 2(1) item 1) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 2) 2023 (PB 111 of 2023) | 31 Oct 2023 (F2023L01455) | 1 Nov 2023 (s 2(1) item 1) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 3) 2023 (PB 125 of 2023) | 30 Nov 2023 (F2023L01573) | 1 Dec 2023 (s 2(1) item 1) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023 (PB 136 of 2023) | 18 Dec 2023 (F2023L01702) | Sch 2: 1 Feb 2024 (s 2(1) item 3)Sch 3: 1 Apr 2024 (s 2(1) item 4)Remainder: 1 Jan 2024 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 1) 2024 (PB 10 of 2024) | 31 Jan 2024 (F2024L00114) | Sch 2: 1 June 2024 (s 2(1) item 3)Remainder: 1 Feb 2024 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 2) 2024 (PB 24 of 2024) | 29 Feb 2024 (F2024L00228) | 1 Mar 2024 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 3) 2024 (PB 32 of 2024) | 28 Mar 2024 (F2024L00411) | 1 Apr 2024 (s 2(1) items 1, 2, 3) | — |
| National Health (Minimum Stockholding) Amendment Determination (No.4) 2024 (PB 49 of 2024) | 30 Apr 2024 (F2024L00502) | Sch 2: 1 Oct 2024 (s 2(1) item 3)Remainder: 1 May 2024 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 5) 2024 (PB 61 of 2024) | 30 May 2024 (F2024L00591) | 1 June 2024 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024 (PB 75 of 2024) | 28 June 2024 (F2024L00809) | Sch 2: 1 Oct 2024 (s 2(1) item 3)Sch 3: 1 Dec 2024 (s 2(1) item 4)Remainder: 1 July 2024 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 7) 2024 (PB 83 of 2024) | 31 July 2024 (F2024L00942) | 1 Aug 2024 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 8) 2024 (PB 90 of 2024) | 28 Aug 2024 (F2024L01065) | 1 Sept 2024 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 9) 2024 (PB 102 of 2024) | 27 Sept 2024 (F2024L01234) | Sch 3: 1 Dec 2024 (s 2(1) item 4)Remainder: 1 Oct 2024 (s 2(1) items 1–3) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024 (PB 121 of 2024) | 30 Oct 2024 (F2024L01383) | Sch 2: 1 Apr 2025 (s 2(1) item 3)Remainder: 1 Nov 2024 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 11) 2024 (PB 135 of 2024) | 29 Nov 2024 (F2024L01521) | 1 Dec 2024 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 12) 2024 (PB 145 of 2024) | 20 Dec 2024 (F2024L01746) | Sch 2 and 3: 1 Apr 2025 (s 2(1) items 3, 4 (first occurring))Sch 4: 1 June 2025 (s 2(1) item 4 (second occurring))Remainder: 1 Jan 2025 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 1) 2025 (PB 11 of 2025) | 29 Jan 2025 (F2025L00053) | Sch 2 and 3: 1 Apr 2025 (s 2(1) items 3, 4)Remainder: 1 Feb 2025 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 2) 2025 (PB 22 of 2025) | 27 Feb 2025 (F2025L00213) | Sch 1: 1 Mar 2025 (s 2(1) item 2)Sch 2: 1 Aug 2025 (s 2(1) item 3) | — |

Endnote 4—Amendment history

| Provision affected | How affected |
| --- | --- |
| **Part 1** |  |
| s 2  | rep LA s 48D |
| s 5  | am F2023L01338 |
| **Schedule 1** |  |
| Schedule 1  | am F2023L01338 |
|  | rs F2023L01455 |
|  | am F2023L01455; F2023L01573 |
|  | ed C3 |
|  | am F2023L01702; F2024L00114 |
|  | ed C5 |
|  | am F2024L00228; F2024L00411; F2024L00502; F2024L00591; F2024L00809; F2024L00942 |
|  | ed C11 |
|  | am F2024L01065; F2024L00502 (Sch 2 item 4 md not incorp); F2024L00809; F2024L01234; F2024L01383 (Sch 2); F2024L01521; F2024L01746 (Sch 2; Sch 3; Sch 4); F2025L00053 (Sch 2; Sch 3); F2025L00213 (Sch 1 item 27 md not incorp), (Sch 2) |